Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital

Similar documents
FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery

Comorbidities in HF COPD Chronic Obstructive Pulmonary Disease Gerasimos Filippatos Athens, Greece

Statins in lung disease

Patient referral for elective coronary angiography: challenging the current strategy

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

COPD as a comorbidity of heart failure in elderly patients

Exercise treadmill testing is frequently used in clinical practice to

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?

Management of the coronary patient in Roberto Ferrari

DECLARATION OF CONFLICT OF INTEREST

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Rikshospitalet, University of Oslo

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Hypertension Management Controversies in the Elderly Patient

Management of Cardiovascular Disease in Diabetes

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Chapter 4: Cardiovascular Disease in Patients With CKD

Supplement materials:

The Clinical Unmet need in the patient with Diabetes and ACS

My Patient Needs a Stress Test

Egyptian Hypertension Guidelines

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Angina or intermittent claudication: which is worse?

Stress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Review of guidelines for management of dyslipidemia in diabetic patients

Estrogens vs Testosterone for cardiovascular health and longevity

HF-PEF: Symptoms, quality of life and mortality/morbidity

Management of COPD and CHF: drugs that should be preferred or avoided

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

The Diabetes Link to Heart Disease

Dyslipidemia in women: Who should be treated and how?

Diagnosis is it really Heart Failure?

CVD Prevention, Who to Consider

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Sleep Apnea and Heart Failure

Blood Pressure Treatment Goals

HFpEF. April 26, 2018

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

The importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher

Heart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF)

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

National Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)

Risk Stratification for CAD for the Primary Care Provider

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

The ACC Heart Failure Guidelines

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Clinical Phenotypes and In-hospital Management and Prognosis in Diabetic versus Non-diabetic Patients with Acute Heart Failure in ALARM-HF Registry

University of Massachusetts Medical School Kimberly A. Fisher University of Massachusetts Medical School Worcester

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

T. Suithichaiyakul Cardiomed Chula

Joshua A. Beckman, MD. Brigham and Women s Hospital

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD

Disclosures (2013 to the present)

Lipid Management 2013 Statin Benefit Groups

Exercise after CABG: The Good The Bad and the Ugly

AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston

Trials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1

Heart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

The ACCELERATE Trial

Mohammad Zubaid, MB, ChB, FRCPC, FACC

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Title for Paragraph Format Slide

2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Heart failure in diabetes: consequences for diagnosis and therapy

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Epidemiologic Measure of Association

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index

Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?

Lnformation Coverage Guidance

Hypertension Update Clinical Controversies Regarding Age and Race

Heart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto

Preventive Cardiology Scientific evidence

CLINICAL OUTCOME Vs SURROGATE MARKER

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

HYPERTENSION: UPDATE 2018

Transcription:

Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital

Disclosures: No conflicts of interest

Common partners, common problems COPD in HF common partners HF in COPD symptoms common problems prognosis diagnosis treatment

How common is COPD in stable HF? 374,893 patients in primary care 25 23,8 20 15 10 5 3,1 0 General Population Heart Failure Hawkins NM. Eur J Heart Fail 2010: 12(1):1-8.

How common is COPD in stable HF? 374,893 patients in primary care 35 30 29,4 25 20 15 10 12,0 16,9 5 3,1 0 General population Elderly > 65 years Heart failure non-smoker Heart failure smoker Hawkins NM. Data on file.

Prevalence of COPD in stable HF in Europe 30 25 20 15 10 5 0 2000 2004 1998 2003 2001 Hawkins NM. Eur J Heart Fail 2009: 11(2):130-139.

45 40 35 30 25 20 15 10 5 0 Prevalence of COPD in acute HF in Europe 1995 1996 1996 1998 2001 2000 2003 2004 2004 2005 Hawkins NM. Eur J Heart Fail 2009: 11(2):130-139.

Prevalence of COPD in stable HF in North America 60 50 40 30 20 10 0 1995 1996 1997 1999 2000 Hawkins NM. Eur J Heart Fail 2009: 11(2):130-139.

Prevalence of COPD in acute HF in North America 40 35 30 25 20 15 10 5 0 1986 1989 1994 1994 1995 1995 1995 1996 1997 1999 1999 1999 2000 2001 2003 2001 2001 Hawkins NM. Eur J Heart Fail 2009: 11(2):130-139.

Increasing prevalence of COPD in HF: cohort series 40 35 First Year Last Year 30 25 20 15 10 5 0 Kaiser Permanente 1974-1994 Boston 1987-1996 Medicare 1991-1997 Medicare 1992-1999 Scotland 1999-2004 Barker DW. Circulation 2006;113:799-805. Polanczyk CA. Arch Intern Med 2000;160:325-332. Baker DW. Am Heart J 2003; 146:258-264. Kosiborod M. Am J Med 2006; 119:616-617 Hawkins NM. Eur J Heart Fail 2010; 12(1):1-8.

Prevalence of COPD in HF: Cardiology vs general medicine 35 30 Cardiology Medicine 25 20 15 10 5 0 1994 n=1298 1995 n=38806 1996 n=19022 1997 n=403 Auerbach AD. Ann Intern Med 2000; 132:191-200. Philbin EF. Am Heart J 2000; 139:491-496. Jong P. Circulation 2003; 108:184-191. Ansari M. J Am Coll Cardiol 2003; 41:62-68.

Prevalence of COPD in HF: Preserved vs reduced EF 60 50 Preserved Reduced 40 30 20 10 0 COPD is more prevalent in HF with preserved EF Hawkins NM. Eur J Heart Fail 2009: 11(2):130-139.

Prevalence of COPD in HF: Socioeconomic status 374,893 patients in primary care 35 Rate Ratio 1.27 [1.05-1.55], p=0.01 30 25 20 15 10 5 0 Least Deprived 2 3 4 Most Deprived Hawkins NM. Eur J Heart Fail 2010: 12(1):1-8.

Prevalence some considerations population spirometry ageing cut-offs risk factors changing criteria smoking pulmonary disease burden definition oedema surveillance spirometry awareness clinical coding screening self reported contact with medication services

Discord between self-reported COPD and spirometry 90 80 Spirometry confirms Spirometry refutes 489 consecutive patients hospitalised with HF 70 60 prevalence of COPD 35% 50 40 30 58,3 33% with self-reported COPD refuted by spirometry 20 10 0 7,2 14,7 Self-report present 19,8 Self-report absent 25% without self-reported COPD airflow obstruction on spirometry Iversen KK. J Intern Med 2008: 264(4):361-369.

Prognostic significance of COPD in HF Independent predictor of 1 year mortality Gustafsson Lee Goldberg 1,36 1,41 1,39 Braunstein Alexander Jong 1,12 1,13 1,19 Senni 1,41 Siirila-Waris 1,20-0,5 0 0,5 1 1,5 2 2,5 Relative Risk or Odds Ratio (± 95% CI) Hawkins NM. Eur J Heart Fail 2009: 11(2):130-139.

Prevalence of HF in COPD Italian Health Search Database n=341,329 7.9% prevalence HF in COPD overall Scottish Continuous Morbidity Record n=377,439 11.9% prevalence HF in COPD overall Cazzola M. Respiration 2010; epub; Hawkins NM. Data on file.

Prevalence of LVSD in COPD high prevalence selected populations severe COPD suspected LVSD coronary disease Rutten FH. Eur J Heart Fail 2006: 8(7):706-711.

Prevalence of unrecognised HF in COPD primary care patients with COPD 65 years (n=405) diagnosis by consensus opinion of expert panel after extensive work-up symptoms and echocardiographic systolic or diastolic dysfunction Rutten FH. Eur Heart J 2005: 26(18):1887-1894.

Survival Prognostic significance of HF in COPD 1.0 0.9 0.8 doubles mortality of patients with COPD primary care patients with COPD 65 years (n=405) 0.7 0.6 COPD COPD GOLD COPD + Heart Failure COPD GOLD + Heart Failure adjusted HR 2.1 (1.2 3.6) 0.5 0 12 24 36 48 60 72 Time (Months) Boudestein LC. Eur J Heart Fail 2009; 11(12):1182-1188.

Relationship between COPD and HF: Causal or confounded? COPD? Causal HF Associated Causal Pro low grade inflammation atherosclerosis myocardial injury FEV 1 predicts CV events CV Risk Factors Contra CV Health Study Copenhagen Study COPD not independent predictor of HF or LVSD

Potential Confounders independent predictors of atherosclerotic events in VALIANT (n=14703) Smoking BP Diabetes Lipids Diet Activity Socioeconomic Obesity Occupation CVD CAD CVA PVD CKD Predictor Hazard Ratio (95% CI) Diabetes 1.36 (1.24-1.50) Age (per 10 years) 1.17 (1.11-1.24) Angina 1.31 (1.19-1.44) Previous MI 1.28 (1.16-1.42) Killip Class 3 1.42 (1.22-1.66) Killip Class 4 1.49 (1.23-1.81) Previous stroke 1.28 (1.12-1.47) Heart failure post-mi 1.19 (1.08-1.31) Heart rate (per 10 bpm) 1.06 (1.03-1.10) Current smoker 1.21 (1.08-1.36) Previous unstable angina 1.17 (1.06-1.30) Hypertension 1.17 (1.06-1.30) Angina post-mi 1.16 (1.05-1.28) Peripheral vascular disease 1.19 (1.05-1.35) Killip Class 2 1.18 (1.03-1.34) New diabetes 1.28 (1.04-1.57) Left bundle branch block 1.23 (1.03-1.45) Weight (per 10 kg) 1.55 (1.07-2.22) Previous CABG 1.19 (1.03-1.37) Previous heart failure 1.13 (1.01-1.26) COPD 0.98 (0.77-1.23) Hawkins NM. Eur J Heart Fail 2009: 11(3):292-298.

THE HF SPECTRUM Less challenging More challenging Young Few co-morbidities Old Multiple comorbidities Polypharmacy

THE HF SPECTRUM Less challenging More challenging Young Few co-morbidities Old Multiple comorbidities Polypharmacy Population

THE HF SPECTRUM Less challenging More challenging Young Few co-morbidities Old Multiple comorbidities Polypharmacy Population Cardiology involvement

Conclusions COPD is common in HF and independently predicts mortality HF is common in COPD and independently predicts mortality Cardiovascular risk factors cluster in patients with COPD As we shall see, numerous symptomatic, diagnostic and therapeutic problems

Thank you Any questions?